Sunday, June 5, 2022, Chicago, Illinois, 7:00 PM – 9:30 PM Central Time (8:00 PM – 10:30 PM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:30 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Ian W Flinn, MD, PhD
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Brian T Hill, MD, PhD
Director, Lymphoid Malignancy Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
Weill Cornell Medicine
New York, New York


Matthew Lunning, DO
Associate Professor
Fred and Pamela Buffett Cancer Center
Associate Vice Chair of Research, Department of Medicine
Assistant Vice Chancellor of Clinical Research
University of Nebraska Medical Center
Omaha, Nebraska

Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Associate Editor, Blood
Vancouver, British Columbia, Canada

Mitchell R Smith, MD, PhD
Clinical Professor of Medicine
George Washington University
Washington, DC

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Kite, A Gilead Company, and Lilly.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:30 PM — Educational Meeting

MODULE 1: Newly Diagnosed Chronic Lymphocytic Leukemia (CLL)

  • Long-term follow-up from studies documenting the efficacy and safety of ibrutinib- and acalabrutinib-based regimens for patients with treatment-naïve CLL
  • Emerging results from the Phase III SEQUOIA trial comparing zanubrutinib to bendamustine/rituximab (BR) as first-line therapy for previously untreated CLL
  • Phase III data sets (eg, ELEVATE-RR, ALPINE studies) documenting the comparative efficacy and tolerability of first- and second-generation Bruton tyrosine kinase (BTK) inhibitors in patients with previously treated CLL; implications for up-front decision-making
  • Extended follow-up with fixed-duration venetoclax/obinutuzumab for older or less-fit patients with previously untreated CLL
  • Outcomes observed with venetoclax-based up-front regimens in fit patients with treatment- naïve CLL in the Phase III GAIA (CLL13) trial
  • Major efficacy and safety findings from the Phase III GLOW trial evaluating ibrutinib in combination with venetoclax as first-line treatment for CLL

MODULE 2: Relapsed/Refractory (R/R) CLL; Novel Investigational Strategies

  • Key factors in the selection and sequencing of therapy for patients who experience relapse on first-line BTK or Bcl-2 inhibition
  • Long-term efficacy and safety results with BTK inhibitors and venetoclax-based therapy in patients with R/R CLL; clinical utility of rechallenging with agents used in a prior line of treatment
  • Current and potential role of PI3K inhibitors in the CLL treatment paradigm
  • Mechanism of action of pirtobrutinib; published clinical trial results, potential clinical role and ongoing and planned studies of pirtobrutinib for CLL
  • Other promising agents and strategies under investigation for CLL

MODULE 3: Follicular Lymphoma (FL)

  • Appropriate integration of obinutuzumab into current FL treatment algorithms; practical implications of the Phase IV GAZELLE study demonstrating the efficacy and safety of a shorter, 90-minute, infusion of obinutuzumab
  • Long-term clinical trial findings with lenalidomide/rituximab for patients with treatment- naïve and R/R FL; current role in clinical practice
  • Available data with and patient selection for treatment with available PI3K inhibitors for FL
  • Mechanistic similarities and differences between the next-generation PI3K inhibitor parsaclisib and currently available drugs in this class; efficacy and safety observed with parsaclisib in the Phase II CITADEL-203 study
  • Incidence of EZH2 mutations in patients with FL; key findings with and optimal use of tazemetostat for previously treated FL with and without EZH2 mutations
  • Mechanism of action of and available safety and efficacy data with investigational bispecific antibodies (eg, mosunetuzumab, glofitamab, epcoritamab) for R/R FL; FDA breakthrough therapy designation for mosunetuzumab and potential clinical role
  • Early results with and ongoing investigation of other novel agents and strategies for FL

MODULE 4: Mantle Cell Lymphoma (MCL)

  • Research database supporting the use of ibrutinib, acalabrutinib or zanubrutinib for R/R MCL; key factors in patient selection for these agents
  • Available data with and ongoing evaluation of BTK inhibitors alone or in combination with other systemic therapies for previously untreated MCL
  • Available clinical trial findings with and potential clinical role of lenalidomide as a component of up-front and/or maintenance therapy for MCL
  • Early-phase research experience with venetoclax alone or combined with other agents for MCL; current nonresearch role and practical implementation of venetoclax therapy
  • Available data, FDA priority review and potential clinical role of parsaclisib
  • Efficacy and safety findings observed in the Phase I/II BRUIN study of pirtobrutinib in patients with R/R MCL; potential clinical role
  • Ongoing investigation of other novel agents and strategies for MCL

MODULE 5: Diffuse Large B-Cell Lymphoma (DLBCL)

  • Improvement in progression-free survival reported from the Phase III POLARIX study comparing polatuzumab vedotin with chemotherapy to R-CHOP for previously untreated DLBCL; implications for clinical practice
  • Early data with and ongoing and planned evaluation of other novel agents (eg, tafasitamab, selinexor, BTK inhibitors) in the first-line setting
  • Available efficacy and safety findings with polatuzumab vedotin in combination with BR for patients with R/R DLBCL; optimal incorporation into current management algorithms
  • Key data leading to the FDA approval of tafasitamab/lenalidomide for R/R DLBCL; patient selection for treatment with this regimen
  • Optimal sequencing and practical implementation of selinexor for R/R DLBCL
  • Principal findings contributing to the recent FDA approval of loncastuximab tesirine for R/R DLBCL; current role in clinical practice
  • Available data with and ongoing and planned evaluation of CD20 x CD3 bispecific antibodies in DLBCL

MODULE 6: Chimeric Antigen Receptor (CAR) T-Cell Therapy

  • Longer-term follow-up from clinical trials evaluating the efficacy and safety of axi-cel, tis-cel and liso-cel for R/R DLBCL
  • Available and emerging results from Phase III studies (eg, ZUMA-7, TRANSFORM, BELINDA) of CAR T-cell therapy as second-line treatment for DLBCL; implications for routine practice
  • Key efficacy and safety data with approved (brexucabtagene autoleucel) and investigational (liso-cel) CAR T-cell platforms for MCL
  • Principal outcomes from pivotal studies (eg, ZUMA-5, ELARA) evaluating CAR T-cell therapy for FL; FDA approval of axi-cel and current role in clinical practice
  • Available findings from the liso-cel monotherapy cohort and the liso-cel/ibrutinib cohort of the Phase I/II TRANSCEND CLL 004 trial for R/R CLL
  • Ongoing studies evaluating CAR T-cell therapy in various lymphoma subtypes; appropriate patient referral

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) CLL, considering clinical presentation, age, performance status (PS), biomarker profile and coexisting medical conditions.
  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for diffuse large B-cell lymphoma (DLBCL) in order to determine the current and potential utility of those agents in clinical practice.
  • Consider patient age, PS and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients about the potential benefits of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL, FL, MCL and DLBCL and thus support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for CLL and various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Hill has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr FlinnConsulting Agreements (to Sarah Cannon Research Institute): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Century Therapeutics, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Great Point Partners LLC, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Unum Therapeutics, Verastem Inc, Vincerx Pharma, YL-Pharma Co Ltd; Research Grants (to Sarah Cannon Research Institute): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals AG, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research and Development Corporation, Unum Therapeutics, Verastem Inc. Dr LeonardConsulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Grail Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Lilly, Merck, Mustang Bio, Pfizer Inc, Roche Laboratories Inc, Second Genome, Sutro Biopharma; Contracted Research: Epizyme Inc, Genentech Foundation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group. Dr LunningConsulting Agreements: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, EUSA Pharma, Fate Therapeutics, Genentech, a member of the Roche Group, Instil Bio, Kite, A Gilead Company, Kyowa Kirin Co Ltd, Legend Biotech, MorphoSys, Myeloid Therapeutics, Novartis, Nurix Therapeutics Inc, Sana Biotechnology, TG Therapeutics Inc. Dr SehnAdvisory Committee and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lundbeck, Merck, MorphoSys, Novartis, Pfizer Inc, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, Verastem Inc; Contracted Research: Teva Oncology. Dr SmithAdvisory Committee: Janssen Biotech Inc; Consulting Agreements: Acrotech Biopharma, CytomX Therapeutics; Contracted Research: Karyopharm Therapeutics; Data and Safety Monitoring Board/Committee: ECOG-ACRIN Cancer Research Group; Speakers Bureau: Acrotech Biopharma, AstraZeneca Pharmaceuticals LP, EUSA Pharma.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Kite, A Gilead Company, and Lilly.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.